leadf
logo-loader
viewRhythm Biosciences Ltd

Rhythm Bioscience tackles bowel cancer with accessible diagnostic tool

Rhythm Biosciences Ltd (ASX:RHY) managing director & CEO Trevor Lockett speaks to Proactive Investors about the health company’s development of a diagnostic tool for detecting colorectal or bowel cancer.
 
ColoSTAT, Rhythm’s antibody-based blood test, was granted a biomarker patent within Europe earlier this year.
 
“Colorectal cancer is one of the major killers globally … it’s also remarkable that colorectal cancer is one of the most curable cancers if detected early,” Lockett says.
 
He continues, “ColoSTAT is a blood test for bowel cancer. It’s based on the detection of proteins that change in concentration in the blood, in the situation of cancer versus normal disease. It’s designed to be a cost-effective, highly clinically effective and accessible test that will be taken by many people.”

Quick facts: Rhythm Biosciences Ltd

Price: 1.34 AUD

ASX:RHY
Market: ASX
Market Cap: $270 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Gunsynd PLC boss sees a lot of upside with portfolio 'geared towards...

Gunsynd PLC's (LON:GUN) Pete Ruse introduces the London-based investment firm to Proactive's Andrew Scott. He says GUN's an investor, first and foremost, in natural resources but also has the benefit of having quite an open investment policy which includes life sciences and gaming as well as...

3 hours, 30 minutes ago

2 min read